ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد ایتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Clinical features and diagnosis of psychiatric disorders in patients with cancer: Overview

Clinical features and diagnosis of psychiatric disorders in patients with cancer: Overview
Authors:
Jacynthe Rivest, MD
Jon Levenson, MD
Section Editors:
Jonathan M Silver, MD
Susan D Block, MD
Deputy Editor:
David Solomon, MD
Literature review current through: Jun 2022. | This topic last updated: May 16, 2022.

INTRODUCTION — Patients with cancer have a high rate of comorbid psychiatric disorders as well as nonspecific psychological distress [1]. The prevalence of comorbid psychiatric disorders and clinically significant psychological distress among patients with cancer may reach as high as 85 percent. However, it is estimated that fewer than 50 percent of cancer patients with psychiatric disorders and distress are identified and referred for appropriate care.

Psychiatric disorders that develop in patients with cancer may be associated with increased mortality. A national registry study identified patients with esophageal cancer (n >1600) who underwent surgery and had no prior history of psychiatric disorders [2]. After adjusting for potential confounding factors (eg, age, marital status, and tumor stage and histology), the analyses found that all-cause mortality was greater among patients who developed psychiatric disorders, compared with patients who were free of psychiatric disorders (hazard ratio 1.7, 95% CI 1.2-2.3).

This topic reviews the clinical features and diagnosis of psychiatric disorders in patients with cancer. The clinical features and assessment of psychiatric disorders in palliative care are discussed separately, as is the management of psychiatric disorders in cancer patients. (See "Approach to symptom assessment in palliative care", section on 'Psychological and cognitive symptoms' and "Management of psychiatric disorders in patients with cancer".)

PREVALENCE OF PSYCHIATRIC COMORBIDITY — Among patients with cancer, comorbid psychiatric disorders are present in at least one-third:

In a meta-analysis of 17 studies in which cancer patients were interviewed (number of patients not reported), the point prevalence of psychiatric disorders (adjustment disorders, anxiety disorders, or depressive disorders) was approximately 38 percent; however, heterogeneity across studies was high [3].

A meta-analysis of eight observational studies included patients with cancer (n = 1448) who were assessed with validated instruments, and found that at least one psychiatric disorder (adjustment, anxiety, depressive, somatic symptom, or substance use disorders; or posttraumatic stress disorder) was present in 32 percent; heterogeneity across studies was significant [4].

A subsequent cross-sectional study of patients with cancer who were interviewed (n >2000) found that at least one mental disorder (eg, adjustment, anxiety, depressive, somatic symptom, or substance use disorders) was present in 32 percent [5].

In addition, multiple studies suggest that mental disorders are more common in patients with cancer than the general population [5-8]. As an example, a national registry study identified patients with cancer (n >300,000) and individuals without cancer (n >3,000,000), and compared the composite incidence of psychiatric disorders (adjustment, anxiety, depressive, somatic symptom, or substance use disorders) in the two groups [9]. After adjusting for age, sex, and education, the analyses showed that the incidence of psychiatric disorders was higher in cancer patients than controls, and the increased rate of mental disorders was greatest in the first week after diagnosis, such that cancer patients were seven times more likely to have a psychiatric disorder (hazard ratio 6.7, 95% CI 6.1-7.4). The magnitude of the elevated rate subsequently decreased, but the prevalence of psychiatric disorders in cancer patients remained elevated 10 years after diagnosis (hazard ratio 1.1, 95% CI 1.1-1.2).

The prevalence of specific psychiatric disorders in patients with cancer are discussed elsewhere in this topic.

ASSESSMENT OF PSYCHIATRIC SYMPTOMS — For clinicians who are assessing psychiatric symptoms in patients with cancer, one of the initial goals is to determine whether the symptoms represent a [10-12]:

Normal reaction to a life-threatening illness.  

Psychiatric disorder (either new onset or recurrence).

Manifestation of cancer itself or its treatment – As an example, primary or metastatic brain cancer can alter cognition, emotions, or behavior. In addition, corticosteroids can induce neuropsychiatric disturbances that range along a spectrum from minor symptoms (eg, irritability, affective lability, or insomnia) to episodes of mania or depression, as well as neurocognitive disorders (delirium or reversible dementia). (See "Major side effects of systemic glucocorticoids", section on 'Neuropsychiatric effects'.)

Psychiatric symptoms/syndromes can appear, disappear, and reappear during any phase of cancer (diagnostic work-up, diagnosis, treatment, survivorship, recurrence of cancer, and palliative care) [10,12].

ADJUSTMENT DISORDERS AND PSYCHOLOGICAL DISTRESS — Exposure to stressful events such as a cancer diagnosis and ensuing treatment can cause psychological distress. In addition, many patients express concerns that stress has “caused” their cancer or that their disease will be exacerbated by further exposure to stress. These concerns can themselves be stressful.

Psychological distress can occur at multiple points: during the diagnostic work-up, at the time of diagnosis, the start of active treatment, and at the time of recurrence [13]. The severity of distress can fluctuate at different times and can manifest with a variety of symptoms, such as fear, apprehension about the future, impaired cognition, worry about roles, and thoughts of death; physical symptoms such as impaired sleep and appetite may also be present. Emotional distress occurs along a continuum ranging from normal sadness and fear to nonspecific distress and poor quality of life to depressive disorders and anxiety disorders [1,13,14]. Although distress is not a psychiatric disorder, clinically significant distress is a criterion for diagnosing adjustment disorder, as well as depressive disorders and anxiety disorders [15]. Distress can occur in family members as well as patients with cancer [16].

Clinically significant psychological distress in patients with cancer is associated with poor outcomes, such as nonadherence to cancer treatment and monitoring, and with poorer quality of life [1]. In addition, distress is associated with decreased survival in many studies [17]. As an example, a nationally representative survey included individuals with a history of cancer (n = 295); after adjusting for potential confounding factors (eg, age, sex, and smoking history), the analyses found that cancer mortality was two times greater among individuals with distress than individuals not distressed (hazard ratio 2.0, 95% CI 1.1-3.7) [18].

Prevalence — The point prevalence of adjustment disorders in patients with cancer is approximately 10 to 20 percent, and nonspecific clinically significant psychological distress occurs in at least 40 percent [13]:

In a meta-analysis of 23 studies in which patients with cancer (number of patients not reported) were interviewed, the estimated point prevalence of adjustment disorder was 19 percent [3]. However, heterogeneity across studies was high.

A subsequent study of patients with cancer who were interviewed (n >2000) found that adjustment disorders were present in 11 percent [5].

Clinically significant psychological distress is observed in roughly 25 to 50 percent of cancer patients [1,13,14,19-21].

Risk factors for emotional distress include [1]:

History of psychiatric disorders

History of physical or sexual abuse

Cognitive impairment

Communication barriers

Uncontrolled symptoms of cancer

Severe comorbid general medical illness

Conflicts with caregiver/family

Living alone

Financial problems

Screening — We suggest that clinicians screen all patients with cancer for distress using a self-report instrument and that screening be implemented with services in place to ensure follow-up for diagnosis and treatment. Screening should occur when the initial diagnosis of cancer is made and periodically thereafter as clinically indicated, especially with changes in cancer or treatment status (eg, recurrence or progression of cancer). This approach is consistent with practice guidelines from the American Society of Clinical Oncology, National Comprehensive Cancer Network, American College of Surgeons, and Institute of Medicine [1,22]. The rationale for screening is that distress is serious, prevalent, under-recognized, and treatable, and that standardized, valid screening tools are available.

Implementing a program to routinely screen patients with cancer for distress may be more successful if hospital/clinic administrators are enlisted to support funding for this effort and training is provided to the staff who will provide the screening and follow-up services [14]. Although patients with cancer largely accept screening, some clinicians think screening is impractical and not useful, and are often reluctant to screen patients because of the time required for administering, scoring, and interpreting the results [14,23,24]. Thus, some institutions do not routinely screen all patients because systematic screening remains a challenge for implementation [25].

We typically use the self-administered Distress Thermometer (figure 1) to screen for distress in patients with cancer. The Distress Thermometer assesses the patient’s level of distress during the past week with a single Likert (visual analogue) scale ranging from 0 (no distress) to 10 (extreme distress) [26]; a score ≥4 suggests clinically significant distress [1,27-32]. The scale is often paired with a checklist of potential stressors, such as practical problems (eg, transportation or occupational difficulties), emotional problems (eg, worry and sadness), and physical problems (eg, fatigue and pain) [28]. The Distress Thermometer has been widely adopted due to its brevity and ease of use, and is available in more than 20 languages [24,25,33]. Although a 2007 pooled analysis of nine studies with nearly 1500 cancer patients concluded that detection of distress with the Distress Thermometer was modest [34], subsequent studies have found its psychometric properties were satisfactory and concluded that the instrument is valid [29,31,32,35-38]. As an example, a prospective study of 462 patients with a variety of cancers found that sensitivity was 87 percent, specificity was 73 percent, and positive predictive value was 53 percent [30].

In screening for distress, reasonable alternatives to the Distress Thermometer include the self-report, two-item Patient Health Questionnaire (PHQ-2) (table 1) and the self-report, seven-item Generalized Anxiety Disorder (GAD-7) scale (table 2) [22].

Although screening for psychological distress in patients with cancer appears to facilitate communication between patients and clinicians, other benefits have not been clearly demonstrated due to mixed results across randomized trials [14]. However, in larger studies and studies that provided adequate staff training, screening led to better outcomes [39]. As an example, one trial (n >700 cancer patients) compared minimal screening with the Distress Thermometer plus usual care with full screening (multiple assessments for distress, anxiety, and depression) plus referrals for psychosocial services as needed [19]. At the three-month follow-up, clinically significant distress was reduced in both groups, and was present in fewer patients who received full screening/referrals, compared with patients who received minimal screening plus usual care (36 versus 49 percent).

Additional information about screening patients with cancer specifically for depressive disorders and anxiety disorders is discussed elsewhere. (See "Clinical features, assessment, and diagnosis of unipolar depressive disorders in patients with cancer", section on 'Screening' and "Clinical features, screening, and diagnosis of anxiety disorders in patients with cancer", section on 'Screening'.)

Diagnosis — Adjustment disorders are frequently diagnosed if cancer leads to psychological distress or behavioral symptoms that do not meet criteria for another specific disorder, such as major depression or generalized anxiety disorder.

According to the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), the diagnosis of adjustment disorder requires each of the following criteria [15]:

Emotional (eg, depression and/or anxiety) or behavioral symptoms (eg, avoiding needles) that occur in response to an identifiable stressor (eg, receiving the diagnosis of cancer) within three months of onset of the stressor.

Symptoms are clinically significant as evidenced by at least one of the following:

Significant distress that exceeds what would be expected given the nature of the stressor

Impaired social or occupational functioning

The syndrome does not meet criteria for another psychiatric disorder (eg, unipolar major depression or generalized anxiety disorder).  

The syndrome does not represent an exacerbation of a preexisting psychiatric disorder.

The syndrome does not represent bereavement.

After the stressor and its consequences have ended, the syndrome resolves within six months.

In making the diagnosis of adjustment disorder, clinicians can specify whether the disorder occurs with:

Anxiety – Nervousness or worry

Depressed mood – Sadness, tearfulness, or hopelessness

Mixed anxiety and depressed mood – Both anxiety and depression

Disturbance of conduct – Behavioral symptoms

Mixed disturbance of emotions and conduct – Both emotional and behavioral symptoms

ANXIETY DISORDERS — Anxiety disorders are common in patients with cancer. (See "Clinical features, screening, and diagnosis of anxiety disorders in patients with cancer".)

DEPRESSIVE DISORDERS — Depressive disorders (table 3A-B) are common in patients with cancer. (See "Clinical features, assessment, and diagnosis of unipolar depressive disorders in patients with cancer".)

NEUROCOGNITIVE SYMPTOMS AND DISORDERS — Cognitive impairment and delirium are common in patients with cancer. (See "Clinical features and diagnosis of cognitive impairment and delirium in patients with cancer".)

OTHER PSYCHIATRIC SYMPTOMS AND DISORDERS

Fatigue — Cancer related fatigue is defined as “a distressing, persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning” [40]. The prevalence, screening, and assessment of fatigue in patients with cancer is discussed separately. (See "Cancer-related fatigue: Prevalence, screening, and clinical assessment".)

Fatigue may be a symptom of a depressive syndrome that warrants treatment, such as major depression (table 3A) or minor depression (table 3B), if the fatigue occurs in conjunction with other depressive symptoms like dysphoria, anhedonia, and suicidal ideation or behavior. (See "Clinical features, assessment, and diagnosis of unipolar depressive disorders in patients with cancer".)

Grief — Anticipatory grief is typically used to describe the natural grief response that terminally ill patients (and their loved ones) experience prior to death [41]. The symptoms include sadness, anxiety, anger, disbelief, and yearning for past health and/or a more hopeful future. Anticipatory grief symptoms can begin far before death and may arise when cancer is first diagnosed. In addition, anticipatory grief is triggered by current losses such as independent functioning, as well as the anticipated loss of life. Anticipation and psychological preparation for death may facilitate adaptation to one’s impending death.

Additional information about the clinical features of grief, including anticipatory grief, is discussed separately. (See "Bereavement and grief in adults: Clinical features".)

Insomnia — Patients with cancer frequently experience insomnia symptoms consisting of transient difficulty initiating or maintaining sleep [42]. In addition, patients often develop insomnia syndromes consisting of repeated insomnia symptoms (eg, more than three times/week for at least one month) that cause distress or impair functioning. As an example, one prospective study of patients (n = 856) who were scheduled for curative surgery for a variety of cancer types found that at baseline, insomnia syndromes were present in approximately 30 percent, and that insomnia symptoms were present in another 30 percent, for a total prevalence of insomnia of approximately 60 percent in this population [43]. The prevalence of insomnia syndromes appeared to be higher than that in the general population.

The pathogenesis of insomnia in patients with cancer often involves multiple predisposing, precipitating, and perpetuating factors [42]. These include cancer per se (eg, tumors that produce steroids or cause pain or dyspnea), as well as cancer treatments (eg, corticosteroids). Other potential causes include stress and anxiety associated with a cancer diagnosis or treatment, poor sleep hygiene (table 4), and cognitive distortions about sleep (eg, the belief that lack of sleep will always affect daytime functioning).

Insomnia in patients with cancer often does not remit. An 18-month, prospective observational study of patients with cancer found that among patients with insomnia syndromes at baseline (n = 240), the syndrome persisted for the duration of follow-up in 38 percent [43].    

For clinicians who want to screen for insomnia, the Edmonton Symptom Assessment Scale (revised version) (table 5) and the Epworth Sleepiness Scale (calculator 1) are recommended by the practice guideline from the Canadian Partnership Against Cancer [42]. The Edmonton Symptom Assessment Scale consists of 10 items, one of which assesses sleep; the scale is completed by the patient, caregiver, or clinician. The Epworth Sleepiness Scale is an eight-item self-report scale that assesses only sleep. However, most clinicians involved in the psychosocial care of cancer survivors do not screen for insomnia. In addition, there are no high-quality studies that demonstrate routine screening of all cancer patients for insomnia improves outcomes.

Assessment and diagnosis of insomnia in the context of general medical settings and palliative care are discussed separately. (See "Risk factors, comorbidities, and consequences of insomnia in adults" and "Evaluation and diagnosis of insomnia in adults" and "Insomnia in palliative care".)

Pain — Pain due to cancer is a symptom that affects most aspects of a person's life, including physical functioning, activities of daily living, mental health, and social interactions. (See "Assessment of cancer pain" and "Overview of cancer pain syndromes".)

Personality traits and disorders — Patients with cancer may manifest problematic personality traits or personality disorders that lead to disruptive behavior [44,45]. As an example, patients with a tendency toward excessive control, demanding behavior, and unrealistic expectations about their care may become angry when treatment does not proceed as they want and complain to the clinician’s supervisor or to licensing agencies or threaten to sue. In addition, patients with antisocial personality disorder often lack empathy and may menace clinicians, which can necessitate hospital security intervention or legal action. Patients with difficult personality traits and disorders can evoke strong emotions in clinicians, including feelings of betrayal, guilt, anger, and intimidation.

The clinical features and diagnosis of personality disorders are discussed separately. (See "Approaches to the therapeutic relationship in patients with personality disorders" and "Overview of personality disorders".)

Posttraumatic stress disorder — Many patients diagnosed with a life-threatening form of cancer experience symptoms of acute stress disorder or posttraumatic stress disorder (PTSD) (table 6), but far fewer patients meet criteria for these syndromes. As an example, a prospective observational study of 166 patients with breast cancer who were interviewed found that after cancer was diagnosed but before treatment commenced, at least one stress disorder symptom was present in 83 percent of patients (mean number of symptoms was three); at the one-year follow-up, at least one symptom was present in 57 percent (mean number of symptoms was two) [46]. By contrast, the full syndrome of acute stress disorder or PTSD was present at the time of the cancer diagnosis and the follow-up in 4 and 2 percent of patients, which appears to be comparable to the rate in the general population.

The epidemiology, clinical features, assessment, and diagnosis of acute stress disorder and PTSD are discussed separately. (See "Acute stress disorder in adults: Epidemiology, pathogenesis, clinical manifestations, course, and diagnosis" and "Posttraumatic stress disorder in adults: Epidemiology, pathophysiology, clinical manifestations, course, assessment, and diagnosis".)

Psychotic disorders — Patients with psychotic disorders such as schizophrenia (table 7), who are hospitalized in an oncology setting, may evoke fear in the staff. In addition, these patients may also be difficult to assess (eg, noncommunicative) and nonadherent with treatment [47]. Psychiatric consultation is recommended to clarify the diagnosis and review treatment. (See "Psychosis in adults: Epidemiology, clinical manifestations, and diagnostic evaluation".)

Sexual dysfunction — Sexual health issues can affect cancer survivors. (See "Overview of psychosocial issues in the adult cancer survivor", section on 'Sexual dysfunction' and "Overview of sexual dysfunction in male cancer survivors".)

Symptoms and disorders in cancer survivors — Patients who survive cancer often experience psychosocial problems. (See "Overview of psychosocial issues in the adult cancer survivor" and "Overview of cancer survivorship care for primary care and oncology providers".)

Symptoms and disorders in family caregivers — Over 50 percent of the care received by patients with cancer is provided by family caregivers, and caregiving is associated with stress and psychiatric problems. As an example, a small cross-sectional study of family caregivers (n = 91) for patients with cancer found that the mental health of caregivers was worse than population norms, and that 62 percent of caregivers reported that their emotional well-being had worsened as a result of caregiving. In addition, a review found that anxiety and depression each occurred in approximately 40 percent of caregivers, and that sleep disturbances and fatigue were common as well [48].

Although there are potential benefits to caregiving, lack of preparation and support for this task may leave caregivers vulnerable to psychiatric disturbances [49,50]. These disturbances in caregivers can adversely affect the emotional well-being of patients, and distress in patients can negatively affect the well-being of caregivers [48].

SUICIDE — Although the prevalence of suicidal ideation in patients with cancer and in the general population appears to be comparable, suicide attempts and deaths are higher in cancer patients [51,52]. Instruments that screen for suicidal behavior lack adequate sensitivity and specificity to accurately predict suicide attempts and deaths [53].

The subsections below discuss suicidal ideation and behavior in patients with cancer. Additional information about suicidality in general is discussed separately. (See "Suicidal ideation and behavior in adults".)

Suicidal ideation — A review found that the prevalence of suicidal ideation in patients with cancer varied greatly across 11 studies, but that the best evidence suggested that thoughts of suicide occurred in roughly 10 to 15 percent of patients, which the authors concluded was comparable to the prevalence in the general population [51]. In a subsequent study of 211 patients with cancer, suicidal ideation was reported by 6 percent [54].

Many patients with cancer are screened for depressive disorders with the self-report, nine-item Patient Health Questionnaire (PHQ-9) (table 8) [55,56], and this instrument includes one item that asks patients whether they have had thoughts that they would be better off dead or thoughts of self-harm.

Patients with cancer who report that they would be better off dead or had thoughts of self-harm should be interviewed to assess the nature of these thoughts and to ascertain whether suicidal ideation is truly present, because these patients may be preoccupied with thoughts of dying from cancer instead of suicide. A retrospective study included outpatients with cancer (n = 330) who completed the PHQ-9 and indicated that they had had thoughts that they would be better off dead or thoughts of self-harm for at least several days [57]. In a subsequent interview about these thoughts, patients responded as follows:

Denied thoughts of suicide – 32 percent of patients

Acknowledged thoughts of being better off dead (passive suicidal ideation) – 39 percent    

Endorsed thoughts of wanting to commit suicide (active suicidal ideation) – 29 percent

Patients with passive or active suicidal ideation should be promptly assessed for risk of suicidal behavior; patients with active suicidal ideation typically require emergent referral to a mental health clinician for evaluation. (See "Suicidal ideation and behavior in adults", section on 'Patient evaluation'.)

Attempts — The risk of suicide attempts is increased in patients with cancer. A national registry study identified patients with a first diagnosis of primary cancer (n >12,000; age 15 to 30 years) and examined suicide attempts in analyses that controlled for age, sex, and prior psychiatric history [52]. In the first year after diagnosis, suicide attempts occurred more than twice as often in the cancer patients than the cancer-free individuals (relative risk 2.3, 95% CI 1.5-3.3), and the elevated risk persisted between one and five years after the diagnosis (relative risk 1.7, 95% CI 1.3-2.3).

Deaths — Numerous studies have established that patients diagnosed with cancer are at increased risk of dying by suicide compared with the general population [51,52,58-63]. The magnitude of the increased risk varies across studies; in several studies, the incidence of suicide was approximately two to three times greater in patients with cancer than cancer-free individuals [51-53,58,60,61,63], but other studies have found that the risk of suicide was up to 11 times greater in cancer patients [51,62]. Nevertheless, the absolute risk is small [64]. As an example, a registry study (n >1,000,000 cancer cases) found that although suicide occurred twice as often in patients with cancer than the general population (0.02 versus 0.01 percent per year), the number of deaths was low [65].

Depression near the end of life may cause the patient to seek assistance in hastening death, which is discussed separately. (See "Physician-assisted dying".)

Risk factors — The following factors are associated with completed suicide in patients with cancer:

Sex (males) – Both males and females with cancer are at increased risk of suicide, but most studies suggest that males commit suicide more often than females [51,53,59,62]. As an example, a national registry study found that the rate of suicide among male cancer patients was 70 percent greater than that in the general population (standardized mortality ratio 1.7, 95% CI 1.6-1.9), whereas the rate in females was only 40 percent greater (standardized mortality ratio 1.4, 95% CI 1.3-1.5) [66]. Another registry study found that the rate of suicide was six times greater in male patients than females [65]. These findings are consistent with the observation in the general population that suicide occurs more often in males.

Time since diagnosis (soon afterwards) – Most studies indicate that suicide is most likely to occur soon (eg, within the first year) after cancer is diagnosed, and that the risk declines over time [51-53,59,60]. As an example, a national registry study found that compared with cancer-free individuals, patients with cancer were [58]:

13 times more likely to commit suicide within one week of receiving the diagnosis (relative risk 12.6, 95% CI 8.6-17.8)

5 times more likely within 12 weeks (relative risk 4.8, 95% CI 4.0-5.8)

3 times more likely within one year (relative risk 3.1, 95% CI 2.7-3.5)

2 times more likely after one year (relative risk 1.8, 95% CI 1.6-2.0)

Eventually (eg, after one to five years), the risk of suicide in patients with cancer appears to decrease to the point that it is comparable to the rate in the general population [52,60].

In one national registry study (n >900,000 cancer patients), the risk of suicide was lower in patients who lived more than 10 years after receiving their diagnosis, relative to the general population (relative risk 0.74, 95% CI 0.65-0.83) [59]. This reduced risk in patients may reflect successful adaptation, or that most of the vulnerable patients have already committed suicide or died from cancer.

Mental illness – Multiple studies indicate that the risk of suicide in patients with cancer is increased in those with comorbid psychiatric disorders (eg, major depression and panic disorder) [51,52].

Impaired physical functioning – Poor physical functioning is associated with an increased risk of suicide in patients with cancer [51,61].

Poor prognosis – Among patients with cancer, the risk of suicide is greater in patients with a poor prognosis than patients with a good prognosis [51,58,59,63]. Nevertheless, the rate of suicide may be elevated even in cancer patients with a good prognosis, compared with the rate in cancer-free individuals [60].

Other factors less frequently associated with suicide include lack of social support and poor pain control [51].

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)

(See "Patient education: Antisocial personality disorder (The Basics)".)

(See "Patient education: Borderline personality disorder (The Basics)".)

(See "Patient education: Post-traumatic stress disorder (The Basics)".)

(See "Patient education: Schizophrenia (The Basics)".)

SUMMARY

Psychiatric disorders that develop in patients with cancer may be associated with increased mortality. (See 'Introduction' above.)

Among patients with cancer, psychiatric comorbidity is present in at least one-third, and the prevalence of mental disorders is greater in cancer patients than the general population. (See 'Prevalence of psychiatric comorbidity' above.)

For clinicians who are assessing psychiatric symptoms in patients with cancer, one of the initial goals is to determine whether the symptoms represent a normal response, a psychiatric disorder (either new onset or recurrence), or a manifestation of cancer itself or its treatment. (See 'Assessment of psychiatric symptoms' above.)  

The point prevalence of adjustment disorders in patients with cancer is approximately 10 to 20 percent, and nonspecific clinically significant psychological distress occurs in at least 25 percent. The diagnosis of adjustment disorder requires each of the following criteria:

Clinically significant emotional or behavioral symptoms that occur in response to an identifiable stressor within three months of onset of the stressor.

The syndrome does not meet criteria for another psychiatric disorder, does not represent an exacerbation of a preexisting psychiatric disorder, and does not represent bereavement.

After the stressor and its consequences have ended, the syndrome resolves within six months.

(See 'Adjustment disorders and psychological distress' above.)

Anxiety disorders, depressive disorders (table 3A-B), cognitive impairment, and delirium are common in patients with cancer. (See "Clinical features, screening, and diagnosis of anxiety disorders in patients with cancer" and "Clinical features, assessment, and diagnosis of unipolar depressive disorders in patients with cancer" and "Clinical features and diagnosis of cognitive impairment and delirium in patients with cancer".)

Patients with cancer may present with other psychiatric symptoms and disorders, including fatigue, grief, insomnia, pain, personality traits and disorders, posttraumatic stress disorder, psychotic disorders, and sexual dysfunction. (See 'Other psychiatric symptoms and disorders' above.)

The risk of suicide attempts and deaths is increased in patients with cancer. Nevertheless, the absolute risk of completed suicide is small. (See 'Suicide' above.)

  1. Holland JC, Andersen B, Breitbart WS, et al. Distress management. J Natl Compr Canc Netw 2013; 11:190.
  2. Wikman A, Ljung R, Johar A, et al. Psychiatric morbidity and survival after surgery for esophageal cancer: a population-based cohort study. J Clin Oncol 2015; 33:448.
  3. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12:160.
  4. Singer S, Das-Munshi J, Brähler E. Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis. Ann Oncol 2010; 21:925.
  5. Mehnert A, Brähler E, Faller H, et al. Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 2014; 32:3540.
  6. Rasic DT, Belik SL, Bolton JM, et al. Cancer, mental disorders, suicidal ideation and attempts in a large community sample. Psychooncology 2008; 17:660.
  7. Dekker J, Braamse A, van Linde ME, et al. One in Three Patients With Cancer Meets the Criteria for Mental Disorders: What Does That Mean? J Clin Oncol 2015; 33:2826.
  8. Suppli NP, Johansen C, Christensen J, et al. Increased risk for depression after breast cancer: a nationwide population-based cohort study of associated factors in Denmark, 1998-2011. J Clin Oncol 2014; 32:3831.
  9. Lu D, Andersson TM, Fall K, et al. Clinical Diagnosis of Mental Disorders Immediately Before and After Cancer Diagnosis: A Nationwide Matched Cohort Study in Sweden. JAMA Oncol 2016; 2:1188.
  10. Holland JC, Breitbart WS, Jacobsen PB, et al. Psycho-Oncology, 2nd ed, Oxford, New York, 2010.
  11. Dubovsky AN, Arvikar S, Stern TA, Axelrod L. The neuropsychiatric complications of glucocorticoid use: steroid psychosis revisited. Psychosomatics 2012; 53:103.
  12. Miller K, Massie MJ. Oncology. In: The American Psychiatric Association Publishing Textbook of Psychosomatic Medicine and Consultation-Liason Psychiatry, Third Edition, Levenson JL (Ed), American Psychiatric Association Publishing, Washington, DC 2019. p.625.
  13. Howell D, Keshavarz H, Esplen MJ, et al. Pan-Canadian practice guideline: Screening, assessment and management of psychosocial distress, major depression and anxiety in adults with cancer, Canadian Partnership Against Cancer (Cancer Journey Advisory Group) and the Canadian Association of Psychosocial Oncology, Toronto 2015.
  14. Carlson LE, Waller A, Mitchell AJ. Screening for distress and unmet needs in patients with cancer: review and recommendations. J Clin Oncol 2012; 30:1160.
  15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.
  16. Schellekens MPJ, van den Hurk DGM, Prins JB, et al. The suitability of the Hospital Anxiety and Depression Scale, Distress Thermometer and other instruments to screen for psychiatric disorders in both lung cancer patients and their partners. J Affect Disord 2016; 203:176.
  17. Chida Y, Hamer M, Wardle J, Steptoe A. Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 2008; 5:466.
  18. Hamer M, Chida Y, Molloy GJ. Psychological distress and cancer mortality. J Psychosom Res 2009; 66:255.
  19. Carlson LE, Groff SL, Maciejewski O, Bultz BD. Screening for distress in lung and breast cancer outpatients: a randomized controlled trial. J Clin Oncol 2010; 28:4884.
  20. Gao W, Bennett MI, Stark D, et al. Psychological distress in cancer from survivorship to end of life care: prevalence, associated factors and clinical implications. Eur J Cancer 2010; 46:2036.
  21. Kim SJ, Rha SY, Song SK, et al. Prevalence and associated factors of psychological distress among Korean cancer patients. Gen Hosp Psychiatry 2011; 33:246.
  22. Andersen BL, DeRubeis RJ, Berman BS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 2014; 32:1605.
  23. Mitchell AJ, Lord K, Slattery J, et al. How feasible is implementation of distress screening by cancer clinicians in routine clinical care? Cancer 2012; 118:6260.
  24. Jacobsen PB. Screening for psychological distress in cancer patients: challenges and opportunities. J Clin Oncol 2007; 25:4526.
  25. Donovan KA, Jacobsen PB. Progress in the implementation of NCCN guidelines for distress management by member institutions. J Natl Compr Canc Netw 2013; 11:223.
  26. Roth AJ, Kornblith AB, Batel-Copel L, et al. Rapid screening for psychologic distress in men with prostate carcinoma: a pilot study. Cancer 1998; 82:1904.
  27. Baken DM, Woolley C. Validation of the Distress Thermometer, Impact Thermometer and combinations of these in screening for distress. Psychooncology 2011; 20:609.
  28. Clover KA, Oldmeadow C, Nelson L, et al. Which items on the distress thermometer problem list are the most distressing? Support Care Cancer 2016; 24:4549.
  29. Chiou YJ, Lee CY, Li SH, et al. Screening for Psychologic Distress in Taiwanese Cancer Inpatients Using the National Comprehensive Cancer Network Distress Thermometer: The Effects of Patients' Sex and Chemotherapy Experience. Psychosomatics 2017; 58:496.
  30. Thalén-Lindström A, Larsson G, Hellbom M, et al. Validation of the Distress Thermometer in a Swedish population of oncology patients; accuracy of changes during six months. Eur J Oncol Nurs 2013; 17:625.
  31. San Giorgi MR, Aaltonen LM, Rihkanen H, et al. Validation of the Distress Thermometer and Problem List in Patients with Recurrent Respiratory Papillomatosis. Otolaryngol Head Neck Surg 2017; 156:180.
  32. Ma X, Zhang J, Zhong W, et al. The diagnostic role of a short screening tool--the distress thermometer: a meta-analysis. Support Care Cancer 2014; 22:1741.
  33. Donovan KA, Grassi L, McGinty HL, Jacobsen PB. Validation of the distress thermometer worldwide: state of the science. Psychooncology 2014; 23:241.
  34. Mitchell AJ. Pooled results from 38 analyses of the accuracy of distress thermometer and other ultra-short methods of detecting cancer-related mood disorders. J Clin Oncol 2007; 25:4670.
  35. Bidstrup PE, Mertz BG, Dalton SO, et al. Accuracy of the Danish version of the 'distress thermometer'. Psychooncology 2012; 21:436.
  36. Chambers SK, Zajdlewicz L, Youlden DR, et al. The validity of the distress thermometer in prostate cancer populations. Psychooncology 2014; 23:195.
  37. Lim HA, Mahendran R, Chua J, et al. The Distress Thermometer as an ultra-short screening tool: a first validation study for mixed-cancer outpatients in Singapore. Compr Psychiatry 2014; 55:1055.
  38. Tang LL, Zhang YN, Pang Y, et al. Validation and reliability of distress thermometer in chinese cancer patients. Chin J Cancer Res 2011; 23:54.
  39. Carlson LE, Waller A, Groff SL, et al. Online screening for distress, the 6th vital sign, in newly diagnosed oncology outpatients: randomised controlled trial of computerised vs personalised triage. Br J Cancer 2012; 107:617.
  40. Bower JE, Bak K, Berger A, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical Oncology clinical practice guideline adaptation. J Clin Oncol 2014; 32:1840.
  41. Kacel E, Gao X, Prigerson HG. Understanding bereavement: what every oncology practitioner should know. J Support Oncol 2011; 9:172.
  42. Howell D, Oliver TK, Keller-Olaman S, et al. A Pan-Canadian practice guideline: prevention, screening, assessment, and treatment of sleep disturbances in adults with cancer. Support Care Cancer 2013; 21:2695.
  43. Savard J, Ivers H, Villa J, et al. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol 2011; 29:3580.
  44. Peteet JR, Meyer FL, Miovic MK. Possibly impossible patients: management of difficult behavior in oncology outpatients. J Oncol Pract 2011; 7:242.
  45. Meyer F, Block S. Personality disorders in the oncology setting. J Support Oncol 2011; 9:44.
  46. Voigt V, Neufeld F, Kaste J, et al. Clinically assessed posttraumatic stress in patients with breast cancer during the first year after diagnosis in the prospective, longitudinal, controlled COGNICARES study. Psychooncology 2017; 26:74.
  47. Freudenreich O, Stern TA. Clinical experience with the management of schizophrenia in the general hospital. Psychosomatics 2003; 44:12.
  48. Northouse L, Williams AL, Given B, McCorkle R. Psychosocial care for family caregivers of patients with cancer. J Clin Oncol 2012; 30:1227.
  49. Blum K, Sherman DW. Understanding the experience of caregivers: a focus on transitions. Semin Oncol Nurs 2010; 26:243.
  50. Mosher CE, Bakas T, Champion VL. Physical health, mental health, and life changes among family caregivers of patients with lung cancer. Oncol Nurs Forum 2013; 40:53.
  51. Robson A, Scrutton F, Wilkinson L, MacLeod F. The risk of suicide in cancer patients: a review of the literature. Psychooncology 2010; 19:1250.
  52. Lu D, Fall K, Sparén P, et al. Suicide and suicide attempt after a cancer diagnosis among young individuals. Ann Oncol 2013; 24:3112.
  53. Anguiano L, Mayer DK, Piven ML, Rosenstein D. A literature review of suicide in cancer patients. Cancer Nurs 2012; 35:E14.
  54. Pranckeviciene A, Tamasauskas S, Deltuva VP, et al. Suicidal ideation in patients undergoing brain tumor surgery: prevalence and risk factors. Support Care Cancer 2016; 24:2963.
  55. Walker J, Waters RA, Murray G, et al. Better off dead: suicidal thoughts in cancer patients. J Clin Oncol 2008; 26:4725.
  56. Walker J, Hansen CH, Hodges L, et al. Screening for suicidality in cancer patients using Item 9 of the nine-item patient health questionnaire; does the item score predict who requires further assessment? Gen Hosp Psychiatry 2010; 32:218.
  57. Walker J, Hansen CH, Butcher I, et al. Thoughts of death and suicide reported by cancer patients who endorsed the "suicidal thoughts" item of the PHQ-9 during routine screening for depression. Psychosomatics 2011; 52:424.
  58. Fang F, Fall K, Mittleman MA, et al. Suicide and cardiovascular death after a cancer diagnosis. N Engl J Med 2012; 366:1310.
  59. Vyssoki B, Gleiss A, Rockett IR, et al. Suicide among 915,303 Austrian cancer patients: who is at risk? J Affect Disord 2015; 175:287.
  60. Carlsson S, Sandin F, Fall K, et al. Risk of suicide in men with low-risk prostate cancer. Eur J Cancer 2013; 49:1588.
  61. Kam D, Salib A, Gorgy G, et al. Incidence of Suicide in Patients With Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg 2015; 141:1075.
  62. Turaga KK, Malafa MP, Jacobsen PB, et al. Suicide in patients with pancreatic cancer. Cancer 2011; 117:642.
  63. Klaassen Z, Jen RP, DiBianco JM, et al. Factors associated with suicide in patients with genitourinary malignancies. Cancer 2015; 121:1864.
  64. Henson KE, Brock R, Charnock J, et al. Risk of Suicide After Cancer Diagnosis in England. JAMA Psychiatry 2019; 76:51.
  65. Kendal WS. Suicide and cancer: a gender-comparative study. Ann Oncol 2007; 18:381.
  66. Yousaf U, Christensen ML, Engholm G, Storm HH. Suicides among Danish cancer patients 1971-1999. Br J Cancer 2005; 92:995.
Topic 4858 Version 27.0

References